A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease

Clinical trial NCT07041099 · RECRUITING

Trial details

NCT number: NCT07041099
Sponsor: Cullinan Therapeutics Inc.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Sjögren Sjogren Disease Sjogren's Syndrome

Start date: 2025-10-01
Primary completion: 2028-03-15
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.